Lung: Extensive-stage SCLC - PCI
Free question published 13 September 2026
A 67-year-old woman with extensive-stage small-cell lung cancer has had a good response to first-line platinum-etoposide chemotherapy, with no brain metastases on staging MRI and WHO performance status 1. Which statement reflects current UK guidance on prophylactic cranial irradiation for her?
- AConsider prophylactic cranial irradiation, as her disease has responded and her performance status is 0 to 2
- BOffer prophylactic cranial irradiation 25 Gy in 10 fractions, as her disease has not progressed on first-line treatment
- COffer prophylactic cranial irradiation only after thoracic consolidation radiotherapy has been completed
- DConsider prophylactic cranial irradiation only where MRI brain surveillance is unavailable
- EDo not offer prophylactic cranial irradiation, as it has no role in extensive-stage disease
Why A is correct
NICE NG122 advises that prophylactic cranial irradiation should be considered for people with extensive-stage small-cell lung cancer and WHO performance status 0 to 2 if their disease has responded to first-line treatment. The wording is consider, a weaker recommendation than the offer used for limited-stage disease, reflecting the more contested evidence in the MRI surveillance era; the limited-stage recommendation specifies 25 Gy in 10 fractions for disease that has not progressed.
And why the others are not
- BIncorrect: this is the limited-stage recommendation (offer, 25 Gy in 10 fractions, disease not progressed); extensive-stage disease carries the weaker consider wording.
- CIncorrect: NICE does not sequence prophylactic cranial irradiation after thoracic consolidation, which is a separate consideration.
- DIncorrect: NICE does not condition prophylactic cranial irradiation on the unavailability of MRI surveillance.
- EIncorrect: prophylactic cranial irradiation is not excluded in extensive-stage disease; it is a considered option in responders.
Source NICE NG122 - Lung cancer: diagnosis and management — National Institute for Health and Care Excellence. Lung cancer: diagnosis and management. NICE guideline NG122. Published 28 March 2019, last updated 08 March 2024.
More free respiratory questions
- Lung: Prophylactic cranial irradiation · 02 September 2026
- Lung: Metastatic NSCLC - first-line immunotherapy · 24 September 2026
- Lung: Limited-stage SCLC thoracic RT · 22 August 2026
Sitting in February? Follow the twenty-week plan.
2,500+ cited questions like this one are waiting in the vault.
See plans and pricing